Results 281 to 290 of about 10,318 (317)
Some of the next articles are maybe not open access.
GLP-1/GLP-1RAs: New Options for the Drug Treatment of NAFLD
Current Pharmaceutical DesignAbstract:Non-alcoholic fatty liver disease (NAFLD) has recently emerged as a global public health concern. Currently, the cornerstone of NAFLD treatment is lifestyle modification and, if necessary, weight loss. However, compliance is a challenge, and this approach alone may not be sufficient to halt and treat the more serious disease development, so ...
Haoran, Jiang, Linquan, Zang
openaire +2 more sources
Can GLP-1RAs redefine transplantation standard of care?
Trends in Pharmacological SciencesMetabolic derangements, particularly obesity and post-transplant diabetes mellitus, remain major challenges in solid organ transplantation, contributing to graft dysfunction and increased morbidity. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have emerged as promising agents due to their glucose-lowering, weight-reducing, and cardiorenal ...
openaire +2 more sources
Kniearthrose: Lange GLP-1RA-Therapie ist krankheitsmodifizierend
Aktuelle RheumatologieEine Gewichtsreduktion gilt als eine der ersten Maßnahmen bei Kniearthrose (KOA). Jüngste Erkenntnisse deuten darauf hin, dass bei Diabetes mellitus Typ 2 empfohlene Glucagonlike-Peptid-1-Rezeptor-Agonisten (GLP-1RAs), die eine Gewichtsreduktion bewirken, eine geringe Verbesserung ...
openaire +1 more source
The benefit of GLP-1RA in different age groups in the cardiovascular outcome trials
Diabetes Research and Clinical Practice, 2021Basem M Mishriky +2 more
exaly
IP06-36 CHARACTERIZING KIDNEY STONE EPISODES BY GLP-1RA MEDICATION IN GLP-1RA USERS
Journal of UrologyShreya Thiagarajan +3 more
openaire +1 more source
Cardiovascular benefits of GLP-1RA and SGLT-2i in women with type 2 diabetes
Primary Care Diabetes, 2022Basem M Mishriky +2 more
exaly